Agile Therapeutics Inc. (NASDAQ:AGRX) fell 3.4% on Monday . The company traded as low as $6.76 and last traded at $6.77, with a volume of 84,279 shares changing hands. The stock had previously closed at $7.01.

AGRX has been the topic of several recent research reports. Zacks Investment Research upgraded Agile Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Tuesday, May 10th. Noble Financial reiterated a “buy” rating and set a $15.00 price objective on shares of Agile Therapeutics in a research report on Friday, July 8th. FBR & Co reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, June 17th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $15.00.

The stock has a 50 day moving average of $7.50 and a 200-day moving average of $6.70. The company’s market cap is $194.87 million.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.11. On average, equities research analysts anticipate that Agile Therapeutics Inc. will post ($1.12) earnings per share for the current year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP raised its stake in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent SEC filing.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.